These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells. Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
7. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640 [TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents. Ghith A; Youssef KM; Ismail NSM; Abouzid KAM Bioorg Chem; 2019 Mar; 83():111-128. PubMed ID: 30343204 [TBL] [Abstract][Full Text] [Related]
12. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation. Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176 [TBL] [Abstract][Full Text] [Related]
14. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study. El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K/AKT/mTOR signaling pathway. Seif SE; Mahmoud Z; Wardakhan WW; Abdou AM; Hassan RA Drug Dev Res; 2023 Aug; 84(5):839-860. PubMed ID: 37016480 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction. Nemr MTM; Elshewy A; Ibrahim ML; El Kerdawy AM; Halim PA Bioorg Chem; 2024 Sep; 150():107566. PubMed ID: 38896936 [TBL] [Abstract][Full Text] [Related]
17. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720 [TBL] [Abstract][Full Text] [Related]
18. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400 [TBL] [Abstract][Full Text] [Related]
20. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation. Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]